ART26.12, a novel fatty acid‐binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models
This work now shows that ART26.12, a novel and selective inhibitor of FABP5, can prevent and treat multiple preclinical models of peripheral neuropathy. Given its excellent safety profile, further work is warranted to develop ART26.12 as a potential therapeutic tool for pain management.
Authors
- W. G. Warren (ORCID: https://orcid.org/0000-0001-5507-1381)
- Wenwen Xue (ORCID: https://orcid.org/0000-0002-4944-277X)
- Ana David-Pereira (ORCID: https://orcid.org/0000-0002-5454-966X)
- Saoirse E. O’Sullivan (ORCID: https://orcid.org/0000-0002-1672-6610)
- Andrew Yates (ORCID: https://orcid.org/0000-0002-8886-4772)
- Christoforos Tsantoulas (ORCID: https://orcid.org/0000-0003-3831-1878)
- Mary Osborn
Publication Details
- Journal
- European Journal of Pain
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1002/ejp.4718
- Citations
- 3
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.70